Accessibility Menu

BlossomHill Therapeutics(NASDAQ) BLSM

Market Cap$599.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)+22%
5 YearN/A
1 YearN/A
1 MonthN/A
$18.44
-5.75%
-1.13Today
After hours$18.52+$0.08 (+0.43%)
BlossomHill Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 18.302026-08-31
BlossomHill Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+14.16%USD 16.032026-08-24
Since inception+22.25%USD 16.002026-08-07

BlossomHill Therapeutics Financials at a Glance

Market Cap

$599.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$31.49

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-1.52 (Low)

Price

$18.44

Volume

101,561.745

Open

$19.57

Previous Close

$18.30

Daily Range

$17.59 - $19.57

52-Week Range

$15.25 - $20.61

Estimated Earnings Date

N/A

BLSM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BlossomHill Therapeutics

BlossomHill Therapeutics, Inc. is a biopharmaceutical company focused on developing small molecule medicines to address unmet medical needs in cancer treatment. Founded in June 2020 and headquartered in San Diego, CA, the company aims to innovate within the biotechnology sector.

Products and Services
  • Development of small molecule therapies for cancer
  • Focus on addressing unmet medical needs in oncology
  • Research collaborations with leading institutions
Growth Outlook
  • Recent IPO in August 2026 positions the company for expansion
  • Strong pipeline of innovative cancer therapies under development
  • Increasing demand for targeted cancer treatments in the market
Financial Highlights
  • Stock price range between 15.25 and 16.05 over the past year
  • Volume of 1,755,772 indicates strong investor interest
  • Market capitalization reflects potential for future growth
BlossomHill Therapeutics, Inc. is strategically positioned in the biotechnology industry, focusing on innovative cancer treatments. The company's commitment to addressing significant medical needs is underscored by its robust product pipeline and research collaborations. The recent IPO and strong stock performance indicate a positive outlook for future growth, making it an intriguing option for potential investors. The increasing demand for targeted therapies in oncology further enhances the company's market potential.
AI Generated • Aug 7, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

63

CEO

Jing Rong Jean Cui, PhD

Website

www.bhtherapeutics.com

Headquarters

San Diego, CA 92121, US

BLSM Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

20.70%

Return on Capital

N/A

Return on Assets

-21.96%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$599.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

30.64M

Volume

101.56K

Avg. Volume

315.59K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$33.56M

EBITDA

-$33.35M

Operating Cash Flow

-$31.92M

Capital Expenditure

-$415.00K

Free Cash Flow

-$32.33M

Cash & ST Invst.

$116.00M

Total Debt

$23.02M

BlossomHill Therapeutics Performance Analysis

BlossomHill Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
BlossomHill Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31N/A
Q12026-03-31N/A
BlossomHill Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD -1.00N/A
20252025-12-31USD -1.9897.3%
BlossomHill Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31N/A
Q12026-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$599.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$9.51M

N/A

Employees

63

N/A

Net Income

-$21.01M

N/A

EBITDA

-$21.98M

N/A

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$116.00M

N/A

Total Debt

$23.02M

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$22.53M

N/A

Short Term Debt

$493.00K

N/A

Return on Assets

-21.96%

N/A

Return on Invested Capital

-26.38%

N/A

Free Cash Flow

-$20.95M

N/A

Operating Cash Flow

-$20.94M

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About BLSM

What is the current price of BlossomHill Therapeutics?

BlossomHill Therapeutics is trading at $18.30 per share.

What is the 52-week range for BlossomHill Therapeutics?

Over the past 52 weeks, BlossomHill Therapeutics has traded between $15.25 and $20.61.

How much debt does BlossomHill Therapeutics have?

As of the most recent reporting period, BlossomHill Therapeutics reported total debt of $279.85M.

How much cash does BlossomHill Therapeutics have on hand?

BlossomHill Therapeutics reported $116.00M in cash and cash equivalents in its most recent financial results.

What is BlossomHill Therapeutics’s dividend yield?

BlossomHill Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services